GlassScriptPhysician profile
Christopher Paul Varacallo
NPI 1821389768
$627,123.21
in general payments reported to CMS, 2019-2025
26 companies · $139K in 2025
The $139K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,109 · 2020: $5,396 · 2021: $6,692 · 2022: $98K · 2023: $165K · 2024: $206K · 2025: $139K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $293K · Honoraria: $141K · Travel and Lodging: $58K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,775 · Food and Beverage: $8,961.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $293,306.62 |
| Honoraria | $141,000.00 |
| Travel and Lodging | $58,011.18 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,775.00 |
| Food and Beverage | $8,961.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $558,347.69 | 2020-2025 | Iovera, Zilretta, Exparel |
| Hydrocision, INC. | $40,403.25 | 2019-2025 | Tenjet |
| Spr Therapeutics, INC | $9,236.67 | 2023-2025 | Sprint Pns System |
| Pacira Therapeutics, INC. | $9,147.75 | 2019-2021 | |
| Curonix LLC | $4,916.33 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Trice Medical, INC. | $1,491.90 | 2022-2025 | |
| Sonex Health, INC. | $1,050.27 | 2020-2025 | Sx-One Microknife |
| Stryker Corporation | $800.20 | 2019-2025 | Triathlon, Mako |
| Bioventus LLC | $364.11 | 2019-2025 | Exogen Ultrasound Bone Healing System, Xcell, Stimrouter Implantable Kit |
| Ferring Pharmaceuticals INC. | $362.39 | 2019-2025 | Euflexxa |
| Ethicon US, LLC | $181.26 | 2023-2024 | Stratafix, Monocryl, Vistaseal |
| Smith+Nephew, INC. | $129.55 | 2019-2025 | Oasis |
| Horizon Therapeutics Plc | $90.05 | 2019-2022 | |
| Zimmer Biomet Holdings, INC. | $89.87 | 2019 | |
| Vericel Corporation | $76.67 | 2023 | Maci |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tenex Health INC. | $76.49 | 2020-2021 | |
| Si-Bone, INC. | $69.49 | 2019-2022 | |
| Depuy Synthes Sales INC. | $48.79 | 2025 | Monovisc, Orthovisc |
| Change Healthcare Technologies, LLC | $46.14 | 2021 | |
| Averitas Pharma INC. | $41.55 | 2025 | Qutenza |
| Mml US, INC. | $34.00 | 2025 | Reactiv8 |
| Endo Pharmaceuticals INC. | $33.41 | 2022-2023 | Xiaflex |
| Orthofix Medical, INC. | $27.40 | 2019 | |
| Medline Industries LP | $25.93 | 2025 | |
| Novo Nordisk INC | $19.94 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $12.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Varacallo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.